ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2330

Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis

Sicong Huang1, Tianrun Cai 2, Daniel Solomon 3, Zeling He 1, Kumar Dahal 2, Chuan Hong 4, Andrew Cagan 5, Seoyoung C. Kim 6, Jacob Joseph 7, Tianxi Cai 8 and Katherine Liao 2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 4Harvard Medical School, Boston, MA, 5Research Information Science and Computing, Partners Healthcare, Boston, 6Brigham and Women’s Hospital and Harvard Medical School, Boston, 7Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital, Boston, MA, 8Harvard T.H. Chan School of Public Health, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: bioinformatics and Electronic Health Record, Heart disease, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: For patients with rheumatoid arthritis (RA), heart failure (HF) is a significant cause of morbidity and mortality.  HF is further classified into 2 subtypes to guide management; HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). HFrEF is commonly observed after myocardial ischemia due to myocyte loss. Chronic inflammation is proposed to play a major role in HFpEF even in the absence of a chronic inflammatory condition. These HF subtypes have been traditionally difficult to study in RA due to the need for a large RA cohort with ejection fraction (EF) data. The objective of this study was to test existing approaches using natural language processing (NLP) to characterize HF subtypes in an electronic medical record (EMR) based RA cohort, and to study differences in clinical risk factors between the two HF subtypes in RA.

Methods: We used data from an EMR-based RA cohort from 2 tertiary care centers. Within this cohort we applied a published protocol using machine learning and natural language processing (NLP) to identify patients with HF.  Among RA patients with HF, we further applied an NLP tool to extract EF data from cardiology reports. Incident HF cases (RA-HF) were identified and matched 1:3 by age, sex, and healthcare utilization to RA patients without HF. HF was classified using the EF data into HFrEF (EF< 40%) and HFpEF (EF >50%). The index date for HF patients was the date of the first EF measurement; thus, this study was limited to HF patients with EF in their records. For controls, the index date was the closest healthcare utilization date within a 6-month window for the EF date. We assessed covariates including RA clinical factors and traditional HF risk factors over the 3-year period prior to the index date.  Using a case-control design, conditional logistic regression was performed to identify risk factors associated with the development of unclassified HF, HFpEF, and HFrEF.

Results: We identified 544 RA subjects with incident HF and EF data. Compared to age and sex matched controls, the RA-HF subjects were less likely to be seropositive or on methotrexate or TNF-α inhibitor (TNFi), and have more comorbid conditions (Table 1). Among RA clinical factors, methotrexate was associated with a lower risk of any HF and HFpEF, and not HFrEF. TNFi use was also associated with reduced risk of any HF, with a stronger trend for reduction in HFpEF (Table 2). Traditional HF risk factors such as myocardial infarction (MI) and coronary artery disease (CAD) were associated with increased risk of any type of HF, with stronger association with HFrEF; valvular disease and atrial fibrillation were more strongly associated with increased risk for HFpEF, consistent with prior literature.

Conclusion: In this preliminary study, we observed that RA factors such as MTX and TNFi use was associated with reduced risk of HF, specifically HFpEF in the former. These differences may provide guidance on understanding the role of inflammation and HFpEF in RA, where anti-inflammatory therapies may provide benefit. Future work is needed to validate incident HF and EF definitions and to take into account the time-varying effect of DMARDs and disease activity on the risk of HF and its subtypes in RA.


RA_HF_ACR_abstract_tab1


RA_HF_ACR_abstract_tab2


Disclosure: S. Huang, None; T. Cai, None; D. Solomon, AbbVie, 2, Abbvie, 2, Amgen, 2, AstraZeneca, 2, Corrona, 2, Genentech, 2, Janssen, 2, Lilly, 2, Pfizer, 2; Z. He, None; K. Dahal, None; C. Hong, None; A. Cagan, None; S. Kim, AbbVie, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Merck, 2, Pfizer, 2, research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics, 2, Roche, 2, Roche/Genentech, 2; J. Joseph, Amgen, 2, Novartis, 2; T. Cai, None; K. Liao, None.

To cite this abstract in AMA style:

Huang S, Cai T, Solomon D, He Z, Dahal K, Hong C, Cagan A, Kim S, Joseph J, Cai T, Liao K. Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-differing-types-of-heart-failure-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-differing-types-of-heart-failure-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology